Go to content





New Strategies for Identifying and Treating Dry Eye Patients

Evening Symposium

Sponsored by : Allergan


17:15 - 18:15

Hall 02

New Strategies for Identifying and Treating Dry Eye Patients


Marguerite McDonald, Steven Wilson, Maurizio Rolando, Peter Simmons


Complex and Underdiagnosed
Treatment Options Preventing Disease Progression in the Moderate Patient
The Role of Osmoprotection in Treating Dry Eye
Advances in Artificial Tear Technology

Dry Eye Disease is an extremely common and complex condition. It is estimated to affect more than 300 million people worldwide and, if inadequately treated, can lead to increasing ocular discomfort, loss of vision quality, and damage to the ocular surface. Recent research suggests that far more people may have tear lm and ocular surface abnormalities associated with Dry Eye Disease than was previously appreciated, and these individuals may be at increased risk of progressive ocular surface damage or poor outcomes following ocular surgery. Ongoing research is also revealing the importance of inflammatory processes and hyperosmotic stress in the pathogenesis and progression of Dry Eye Disease, and this is driving the development of new treatment strategies. This symposium will open with a discussion of the challenges of identifying and diagnosing Dry Eye Disease, particularly among patients who may be asymptomatic or unaware that their symptoms are indicative of a potentially serious problem that should be treated. This will be followed by an overview of treatment options with an emphasis on the bene ts of anti-inflammatory therapy. Recent findings on the benefits of topical cyclosporine in patients with moderate Dry Eye will be presented. The final presentations will discuss the value of osmoprotection in treating Dry Eye Disease and recent advances in artificial tear technology. A new artificial tear will be described that not only helps lubricate the ocular surface, but also enhances the lipid layer of the tear lm and provides osmoprotection for corneal epithelial cells.




Back to content | Back to main menu